Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-ROR1 messenger RNAs with partial complementarity to the shROR1 guide strand refers to a collection of transcripts that are unintentionally silenced by short hairpin RNAs (shRNAs) designed to target the ROR1 (Receptor tyrosine kinase-like orphan receptor 1) gene. This off-target effect is primarily driven by the "seed sequence" of the shRNA, which consists of nucleotides 2 through 7 or 8 of the guide strand. These sequences can bind with partial complementarity to the 3' untranslated regions (UTRs) of various essential genes, leading to their degradation or translational repression (Putzbach et al., 2017, eLife). The broad silencing of these essential survival genes triggers a potent form of cell death known as Death Induced by Survival gene Elimination (DISE) (Gao et al., 2018, Nature Communications). In the context of oncology research, this phenomenon has caused significant confusion, as the cell death observed upon ROR1 knockdown was often mistakenly attributed to the loss of ROR1 itself rather than these off-target effects. This highlights a major challenge in RNA interference (RNAi) therapeutics, where the specificity of the guide strand is paramount to avoiding unintended toxicity. These mRNAs are not therapeutic targets in the traditional sense but are critical factors in understanding the safety profile and mechanism of action of RNAi-based tools and drugs. Consequently, researchers must employ rigorous controls, such as C911 controls or multiple independent sequences, to distinguish between true target-mediated effects and DISE-mediated off-target toxicity.
RNA interference-mediated gene silencing via seed-sequence complementarity in the 3' UTR
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-ROR1 messenger RNA with partial complementarity to the shROR1 guide strand.